11.15.19
The Lubrizol Corporation has announced that its contract development and manufacturing organization (CDMO), Particle Sciences, is to be renamed Lubrizol Life Science Health (LLS Health).
The name change reflects the CDMO’s incorporation into the new Lubrizol Life Science business group, which brings together Lubrizol’s Personal, Home and Health Care business units, as part of a previous reorganization. This announcement follows Lubrizol’s acquisition of Bavaria Medizin Technologie GmbH, a German contract development and manufacturing organization of intravascular and nonvascular devices.
These moves demonstrate that Lubrizol is continuing to expand its concept-to-commercialization solutions for medical device and pharmaceutical companies as part of its LLS Health business. To this end, LLS Health announced its expanded commercial-scale capabilities for drug product manufacturing with the opening of its new 5,000 sq. ft. commercial manufacturing facility in Bethlehem, Pa., as part of a $60 million investment.
“As part of Lubrizol Life Science, we can share and draw upon the resources that come with being part of a large corporation to provide customers with greater support and the market insights that help them meet their goals,” said Barbara Morgan, global business director, Pharmaceutical Solutions, LLS Health. “We are focused on expanding and strengthening our internal capabilities so we can continue to sustainably innovate the way we develop and manufacture drug products in partnership with customers, particularly those complex and differentiated products which require additional expertise and experience.”
As one of the first projects at its new production facility, LLS Health has produced a customer’s first set of three registration batches, an aseptic fill to be incorporated into a novel sterile multi-use topical ophthalmic delivery device.
“We have built a strong reputation for complex drug product expertise with a flexible and proactive approach to solving drug development challenges,” said Dr. Robert Lee, president, CDMO Division, LLS Health. “As LLS Health, this expertise and flexibility will continue, backed by the collective expertise of Lubrizol Life Science, and ongoing investments in our team and facilities.”
The name change reflects the CDMO’s incorporation into the new Lubrizol Life Science business group, which brings together Lubrizol’s Personal, Home and Health Care business units, as part of a previous reorganization. This announcement follows Lubrizol’s acquisition of Bavaria Medizin Technologie GmbH, a German contract development and manufacturing organization of intravascular and nonvascular devices.
These moves demonstrate that Lubrizol is continuing to expand its concept-to-commercialization solutions for medical device and pharmaceutical companies as part of its LLS Health business. To this end, LLS Health announced its expanded commercial-scale capabilities for drug product manufacturing with the opening of its new 5,000 sq. ft. commercial manufacturing facility in Bethlehem, Pa., as part of a $60 million investment.
“As part of Lubrizol Life Science, we can share and draw upon the resources that come with being part of a large corporation to provide customers with greater support and the market insights that help them meet their goals,” said Barbara Morgan, global business director, Pharmaceutical Solutions, LLS Health. “We are focused on expanding and strengthening our internal capabilities so we can continue to sustainably innovate the way we develop and manufacture drug products in partnership with customers, particularly those complex and differentiated products which require additional expertise and experience.”
As one of the first projects at its new production facility, LLS Health has produced a customer’s first set of three registration batches, an aseptic fill to be incorporated into a novel sterile multi-use topical ophthalmic delivery device.
“We have built a strong reputation for complex drug product expertise with a flexible and proactive approach to solving drug development challenges,” said Dr. Robert Lee, president, CDMO Division, LLS Health. “As LLS Health, this expertise and flexibility will continue, backed by the collective expertise of Lubrizol Life Science, and ongoing investments in our team and facilities.”
